SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year.